English
Home > Products > 2,4,5,6-Tetraaminopyrimidine sulfate

China 2,4,5,6-Tetraaminopyrimidine sulfate Factory

We'll dedicate ourselves to offering our esteemed customers together with the most enthusiastically thoughtful solutions for 2,4,5,6-Tetraaminopyrimidine sulfate,CAS NO 49647-58-7,49647-58-7,CAS NO 5392-28-9,5392-28-9, "Passion, Honesty, Sound service, Keen cooperation and Development" are our objectives. We have been here anticipating good friends all over the environment!
2,4,5,6-Tetraaminopyrimidine sulfate, We believe with our consistently excellent service you can get the best performance and cost least goods from us for a long term . We commit to provide better services and create more value to all our customers. Hope we can create a better future together.

Related Products

Hot Products

  • Prucalopride Succinate

    Prucalopride Succinate

    Product Name:Prucalopride Succinate
    Molecular Formula:C22H32ClN3O7
    Molecular Weight:485.96
    CAS Registry Number:179474-85-2
  • Methyl 4-chloropicolinate

    Methyl 4-chloropicolinate

    Product Name:Methyl 4-chloropicolinate
    Molecular Formula:C7H6ClNO2
    Molecular Weight:171.58
    CAS Registry Number:24484-93-3
  • Methyldopa

    Methyldopa

    Product Name:Methyldopa
    Molecular Formula:C10H13NO4
    Molecular Weight:211.22
    CAS Registry Number:555-30-6
  • (2S,5R)-2-carbamoyl-7-oxo-1,6-diazabicyclo[3.2.1]octan-6-yl sulfate

    (2S,5R)-2-carbamoyl-7-oxo-1,6-diazabicyclo[3.2.1]octan-6-yl sulfate

    Product Name:(2S,5R)-2-carbamoyl-7-oxo-1,6-diazabicyclo[3.2.1]octan-6-yl sulfate
    Molecular Formula:C17H28N4O5
    Molecular Weight:368.43
    CAS Registry Number:1174020-64-4
  • (R)-(-)-4-Phenyl-2-oxazolidinone

    (R)-(-)-4-Phenyl-2-oxazolidinone

    Product Name:(R)-(-)-4-Phenyl-2-oxazolidinone
    Molecular Formula:C9H9NO2
    Molecular Weight:163.17
    CAS Registry Number:90319-52-1
  • Gabexate mesylate

    Gabexate mesylate

    Product Name:Gabexate mesylate
    Molecular Formula:C17H27N3O7S
    Molecular Weight;417.48
    CAS Registry Number;56974-61-9
  • Related Blog
  • Reviews

  • Outsourcing of API Manufacturing – Are Strict Regulation and Quality Checks Necessary?

    API is fundamental to the modern drug manufacturing process and cutting cost should not be the only criteria that can be applied to the production of an active pharmaceutical ingredient as it can adversely affect human health if the above-mentioned regulations and practices are not followed strictly.

  • Caffeine CAS No.58-08-2

    Caffeine (CAS No.58-08-2) is a xanthine alkaloid compound, a central nervous stimulant that temporarily drives away drowsiness and restores energy, and is used clinically to treat neurosis and coma recovery. Caffeinated coffee, tea, soft drinks and energy drinks are very popular, so caffeine is also the most commonly used psychotropic drug in the world.

  • What Is Ursodeoxycholic Acid Used For?

    Ursodeoxycholic acid is a cholelithiant commonly used in the gastroenterology department, and also a cholelithiasis dissolving agent, so it can be used in the treatment of gallstones under normal circumstances, on the premise...

  • What is an Active Pharmaceutical Ingredient (API in Pharma)?

    Sandoo Pharmaceutical is a professional active pharmaceutical intermediate manufacturer, producing high quality APIs. Sandoo Pharmaceutical provides a wide range of active pharmaceutical intermediates.

  • Pharmaceutical Intermediates Manufacturers - Something You Need to Know About Pharma Intermediates Industry

    Pharmaceutical intermediates are actually chemical raw materials or chemical products that need to be used in the synthesis of drugs. Such chemical products can be produced in ordinary chemical plants without obtaining a pharmaceutical production license. As long as the technical indicators meet certain level requirements, they can be used to participate in the synthesis and production of drugs.

  • FDA approves lorlatinib for second- or third-line treatment of ALK-positive metastatic NSCLC

    On November 2, 2018, the Food and Drug Administration granted accelerated approval to lorlatinib (LORBRENA, Pfizer, Inc.) for patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) whose disease has progressed on crizotinib and at least one other ALK inhibitor for metastatic disease or whose disease has progressed on alectinib or ceritinib as the first ALK inhibitor therapy for metastatic disease.

Send Inquiry

Hit enter to search or ESC to close
X
We use cookies to offer you a better browsing experience, analyze site traffic and personalize content. By using this site, you agree to our use of cookies. Privacy Policy
Reject Accept